Serum Amyloid A1 Antibody (Reu86.5)

• Reactivity: Hu, Mu
• Applications: WB, ELISA, IHC
• Clone: Reu86.5
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: 0.1 mg/ml

Serum Amyloid A1 Antibody (Reu86.5) Summary

• Description: Novus Biologicals Mouse Serum Amyloid A1 Antibody (Reu86.5) (NBP3-11246) is a monoclonal antibody validated for use in IHC and WB. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: The antibody is raised against human SAA and Helix Pomatia Haemocyanine.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: SAA1
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Immunoassay
  • Immunohistochemistry-Frozen
  • Immunohistochemistry-Paraffin
  • Western Blot
• Application Notes: For Western blotting and Immunohistochemistry dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10.

Packaging, Storage & Formulations

• Storage: Store at 4C.
• Buffer: 0.2 um filtered solution in PBS, 0.1% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.1 mg/ml
• Purity: Protein G purified

Alternate Names for Serum Amyloid A1 Antibody (Reu86.5)

• MGC111216
• PIG4
• SAA
• SAA1
• SAA2
• serum amyloid A protein
• Serum Amyloid A1
• TP53I4
• tumor protein p53 inducible protein 4

Background

The serum amyloid A (SAA) family comprises a number of differentially expressed apolipoproteins, acute-phase SAA1 and SAA2, the former being the major component in plasma, and constitutive SAAs (C-SAAs). Although the liver is the primary site of synthesis of both SAA types extrahepatic production has been reported. The in vivo concentrations increase by as much as 1000-fold during inflammation. Several studies have stressed its importance in the diagnosis and monitoring of various diseases. Pathological SAA values are often detected in association with normal CRP concentrations; SAA rises earlier and more sharply than CRP.
Recently, a broader view of SAA expression and function has been emerging. Expression studies show production of SAA proteins in histologically normal, atherosclerotic, Alzheimer, inflammatory, and tumor tissues. SAA has been found to have binding sites for high density lipoproteins, calcium, laminin, and heparin/heparan-sulfate. Also adhesion motifs were identified and new functions, affecting cell adhesion, migration, proliferation and aggregation discovered. These findings emphasize the importance of SAA in various physiological and pathological processes, including inflammation, atherosclerosis, thrombosis, AA-amyloidosis, rheumatoid arthritis, and neoplasia. SAA has also a number of immunomodulatory roles, it can induce chemotaxis and adhesion molecule expression, has cytokine-like properties and can promote the upregulation of metalloproteinases. It enhances the binding of high-density lipoprotein to macrophages and thus helps in the delivery of lipids to sites of injury for use in tissue repair. It is thus thought to be an integral part of the disease processes. In addition, recent experiments suggest that SAA may play a "housekeeping" role in normal human tissues.
Elevated levels of SAA over time predispose to secondary amyloidosis, extracellular accumulation of amyloid fibrils, derived from a circulating precursor, in various tissue and organs. The most common form of amyloidosis occurs secondary to chronic inflammatory disease, particularly rheumatoid arthritis.
The antibody is raised against human SAA and Helix Pomatia Haemocyanine. It reacts with the SAA-1 type.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: SAA1